Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Patrick M Sweeney & Associates Inc.

Patrick M Sweeney & Associates Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,066 shares of the medical research company’s stock after acquiring an additional 22 shares during the period. Patrick M Sweeney & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $555,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TMO. Legacy Investment Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $26,000. Peterson Financial Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $27,000. Missouri Trust & Investment Co acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Finally, Decker Retirement Planning Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $43,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 1.5 %

TMO stock opened at $583.43 on Tuesday. The company has a fifty day moving average price of $533.60 and a 200 day moving average price of $569.81. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The company has a market cap of $223.16 billion, a price-to-earnings ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Morgan Stanley dropped their price objective on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a report on Monday, January 13th. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Scotiabank began coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price target for the company. Finally, Stephens began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target for the company. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total value of $5,581,200.00. Following the transaction, the chief executive officer now directly owns 33,608 shares of the company’s stock, valued at approximately $18,757,296.96. The trade was a 22.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 34,850 shares of company stock valued at $19,123,197. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.